• increased risk of death when administered to target a haemoglobin of 12 g/ dl (7.5 mmol/ l) in patients with active malignant disease receiving neither chemotherapy nor radiation du
ре • повишен риск от смърт, когато се прилага за достигане на хемоглобин 12 g/ dl (7, 5 mmol/ l)